List of Seysara drug patents
Seysara is owned by Almirall.
Seysara contains Sarecycline Hydrochloride.
Seysara has a total of 4 drug patents out of which 0 drug patents have expired.
Seysara was authorised for market use on 01 October, 2018.
Seysara is available in tablet;oral dosage forms.
Seysara can be used as a method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride, a method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt; a method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt, a method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg or 150 mg equivalent doses, a method for treating a patient 9 years of age and older suffering from an inflammatory skin disorder of non-nodular moderate to severe acne vulgaris comprising administering an effective amount of sarecycline hydrochloride.
Drug patent challenges can be filed against Seysara from 2022-10-01.
The generics of Seysara are possible to be released after 09 February, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8318706 | ALMIRALL | Substituted tetracycline compounds |
May, 2031
(7 years from now) | |
| US9255068 | ALMIRALL | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
Feb, 2033
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9481639 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Aug, 2028
(5 years from now) | |
| US8513223 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Dec, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 1, 2023 |
Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient
NCE-1 date: 2022-10-01
Market Authorisation Date: 01 October, 2018
Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg...
Dosage: TABLET;ORAL
SEYSARA family patents
20
United States
11
Japan
10
European Union
6
Canada
4
Spain
3
Denmark
3
Portugal
3
Poland
3
Slovenia
2
Australia
2
Israel
2
Hong Kong
2
Turkey
2
Lithuania
1
Croatia
1
Korea, Republic of
1
Cyprus
1
Mexico
1
Brazil
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic